Skip to main content
S 2665 115th Congress Senate Health Administrative law and regulatory procedures Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Drug, alcohol, tobacco use Food and Drug Administration (FDA) Government information and archives Health information and medical records Medical ethics Prescription drugs

A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and…

Show full title

A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.

Introduced: April 12, 2018 Introduced by: Young, Todd Republican · Indiana See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 12, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 12, 2018
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.

The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.

What's happening now April 12, 2018

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
  • S 2680 Related bill Opioid Crisis Response Act of 2018
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2665: A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.. 115th Congress. Open America. https://openamerica.io/bill/115-S-2665/
MLA
"S. 2665: A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-2665/.
Bluebook (legal)
S. 2665, 115th Cong. (2026), https://openamerica.io/bill/115-S-2665/.
Markdown link
[S. 2665: A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.](https://openamerica.io/bill/115-S-2665/)
Report a problem